Kura Oncology Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Kura Oncology Stock Summary

Kura Oncology competes with ArriVent BioPharma,, Xencor, Eyepoint Pharmaceuticals, Maravai Lifesciences, and Phathom Pharmaceuticals. Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. Kura Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 123 people.

Kura Oncology Key Financial Ratios

Kura Oncology Key Balance Sheet Accounts

Kura Oncology Key Income Statement Accounts

Kura Oncology Key Cash Accounts

Kura Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Kura Oncology's current stock value. Our valuation model uses many indicators to compare Kura Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kura Oncology competition to find correlations between indicators driving Kura Oncology's intrinsic value. More Info.Kura Oncology is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, Kura Oncology's Return On Equity is projected to slightly grow based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kura Oncology's earnings, one of the primary drivers of an investment's value.

Kura Oncology Systematic Risk

Today, most investors in Kura Oncology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Kura Oncology's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Kura Oncology growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Kura Oncology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Kura Oncology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Kura Oncology based on widely used predictive technical indicators. In general, we focus on analyzing Kura Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Kura Oncology's daily price indicators and compare them against related drivers.

When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.